Diko Kazandjian
@dikokaz
Professor of Medicine, Myeloma Program @SylvesterCancer @univmiami
ID: 276053436
02-04-2011 15:08:26
713 Tweet
467 Takipçi
387 Takip Edilen
URGENT COMMUNIQUE 1. A MASSIVE AND COORDINATED PHYSICAL ATTACK WAS LAUNCHED ON BISHOPS, PRIESTS, DEACONS, SEMINARIANS, AND OTHER ARMENIAN COMMUNITY MEMBERS IN JERUSALEM. SEVERAL PRIESTS, STUDENTS OF THE ARMENIAN THEOLOGICAL ACADEMY, AND INDIGENOUS ARMENIANS ARE SERIOUSLY INJURED
BREAKING: ANCA welcomes strong Robert F. Kennedy Jr stand: “I want to commit this country to the restoration of the sovereignty of #Armenia and #Artsakh, and to the restoration of its territory. Instead of starting another war somewhere, I want to stop one.”
WCC Defends Rights of Armenian community in Jerusalem: World Council of Churches - World Council of Churches (WCC) - is “deeply disturbed” by reports of continuous assaults on the Armenian community and other Palestinian residents of Jerusalem. Follow SaveTheArQ
“Precognition” in myeloma. The most comprehensive AI assisted individualized risk classifier in MM @JCO_ASCo by Francesco Maura Sylvester Comprehensive Cancer Center. In addition to clinical features prediction model accounts for 20 genomic features including APOBEC ascopubs.org/doi/10.1200/JC… #msmm
Love this ASH Clinical News editorial joining the chorus to blast the absurdity of ABIM's MOC, "a recertification system woefully misaligned with its avowed purpose: to ensure that practicing physicians possess clinical competence |To Kill a MOC(kingbird) ashpublications.org/ashclinicalnew…
Dr. Kelly Norsworthy Kelly Norsworthy, MD was appointed Acting Associate Director for Research Mentorship in the Oncology Center of Excellence. She will continue her role as Deputy Division Director for the Division of Hematologic Malignancies I. #OCECareers
BPDCN International Registry is a collaboration of hospitals, specialists, and patients on BPDCN, and it is growing rapidly, involving people from various continents. #ASHAnnualMeeting #BPDCNRegistry, OncoDaily Immune Oncology Research Institute Naveen Pemmaraju, MD Rami komrokji youtube.com/watch?v=5s8Trz…
March is Multiple Myeloma Awareness Month! This week, we had full program in Coral Gables. The coming weeks, we will have great programs in downtown Miami and in Deerfield. Don’t miss these events! #mmsm International Myeloma Foundation Multiple Myeloma RF HealthTree Foundation Sylvester Comprehensive Cancer Center #miami University of Miami
The evolution of response assessment in MM Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 C. Ola Landgren, M.D. Ben Diamond, MD
Where have we or currently in for RRMM treatment #immunotherapy with Ken Shain. C. Ola Landgren, M.D.
In a ‘Historical’ Moment FDA Committee Rules on a Faster Way to Approve Therapies for Myeloma Honored to present EVIDENCE meta-analysis, work I pioneered 15 yrs ago. Congrats also to I2TEAMM International Myeloma Foundation Multiple Myeloma RF #mmsm HealthTree Foundation Sylvester Comprehensive Cancer Center news.med.miami.edu/multiple-myelo…
#mmsm Multiple Myeloma RF With MRD as early endpoint for accelerated approval of new multiple myeloma drugs, patients' access to new therapies will be much quicker. Instead of waiting for 10-15 yrs, new drugs can be available in 3-5 yrs. Here is how it works: vjhemonc.com/video/mzdrxxne…
Clearing the path for MRD as early endpoint in multiple myeloma. Conversation with C. Ola Landgren, M.D. of Sylvester Comprehensive Cancer Center. cancerletter.com/conversation-w…
IsaVRD. More is better. For TI NDMM <80yo. C. Ola Landgren, M.D. Sylvester Comprehensive Cancer Center OncoDaily